P.S. Free & New ALS-Con-201 dumps are available on Google Drive shared by DumpsMaterials: https://drive.google.com/open?id=1rOC5EiWrA7wd-7GoDGsALMhgVdh2Eq6R
With the help of DumpsMaterials’s marvelous brain dumps, you make sure your success in ALS-Con-201 certification exam with money back guarantee. DumpsMaterials serves a huge network of its clientele with the state of the art and exam-oriented short-term study content that requires as little as a two-week time to get ready the entire ALS-Con-201 Certification syllabus.
| Section | Objectives |
|---|---|
| Customer Engagement and Field Operations | - Territory and Account Management
|
| Data, Compliance, and Governance | - Compliance and Security
|
| Agentforce Life Sciences Consulting Fundamentals | - Platform and Solution Architecture
|
| Agentforce and AI Capabilities | - AI and Automation
|
>> ALS-Con-201 Online Lab Simulation <<
ALS-Con-201 exam dumps will give you enough information that you don't requirement to seek out any other source. DumpsMaterials can save you valuable time and money, resulting in satisfying results. ALS-Con-201 exam dumps will increase your level of preparation in minimum time. It's the perfect time to take the right decision. Download DumpsMaterials Salesforce ALS-Con-201 Exam Dumps now to proceed successfully in your professional career.
NEW QUESTION # 21
Choose 1 option.
Cumulus Pharma requires that once a field sales rep finalizes and submits a visit report, it must become immutable and no further edits should be allowed.
Which configuration ensures this behavior?
Answer: B
Explanation:
The correct answer is C because the requirement is to lock a submitted visit report so it can no longer be edited. Salesforce Life Sciences Visit Management supports compliant planning, execution, and reporting for provider visits, and Salesforce Help directs administrators to use the Visit Management Admin Console to configure what fields users can see and how users can interact with and manage visit records.
A submitted visit report often represents a compliance-sensitive record, especially in life sciences, where visit details, sampling activity, consent capture, and inquiry handling may need to remain auditable after submission. Enabling VisitLockHandler enforces the locking behavior, while leaving Unlock submitted visit unchecked prevents the record from being reopened or edited after final submission. This configuration best matches the requirement that the submitted visit report become immutable.
Option A is incorrect because VisitAutoSaveHandler relates to saving visit data, and checking "Allow edits after submission" would contradict the stated requirement. The business specifically wants no further edits after submission. Option B is also incorrect because disabling a permissions handler and setting the status to Closed does not directly enforce immutable submitted-visit behavior. Status alone is not the same as a record lock. Therefore, the consultant should enable VisitLockHandler and ensure submitted visits remain locked by unchecking Unlock submitted visit in the Admin Console.
=========
NEW QUESTION # 22
Choose 1 option.
A field sales rep attempts to add Immunexis to the Product Detailing section during a visit, but the product does not appear in the search results. The product record exists in Salesforce. The product must be explicitly enabled for use in visit discussions.
What should be configured in the Visit Administration tile on the Agentforce Life Sciences for Customer Engagement Admin Console?
Answer: C
Explanation:
The correct answer is B because the product must be enabled for discussion in the visit-detailing experience. Salesforce's Life Sciences Visit Management developer documentation states that information entered in a provider visit typically includes product details, product messages, presentations, marketing items, and samples. Salesforce Trailhead also explains that Life Sciences Cloud uses product administration and product-message configuration to ensure reps only promote and discuss therapies within approved guardrails.
The scenario says the product exists in Salesforce, but it does not appear when the rep tries to add it to the Product Detailing section during a visit. That means the issue is not product creation; it is visit-discussion eligibility. The consultant should configure Product Discussion Settings in the Visit Administration area so Immunexis is available for product detailing and visit discussions.
Option A is incorrect because Territory Product Alignment Rules determine which products are aligned to territories, but the question specifically says the product must be explicitly enabled for use in visit discussions. Territory alignment alone does not guarantee the product appears in the Product Detailing search. Option C is also incorrect because Visit Record Type Mappings control record-type behavior, not whether a product can be discussed. Therefore, the correct configuration is Product Discussion Settings.
NEW QUESTION # 23
Choose 1 option.
An Agentforce Life Sciences Consultant has configured the Medical Inquiry process for Cumulus Pharma. When a field sales rep submits a signed inquiry, the status correctly updates to "Submitted," but the Case record remains owned by the rep instead of being automatically routed to the Medical Science Liaisons (MSLs).
Which trigger handler is inactive?
Answer: A
Explanation:
The correct answer is A because the symptom is specifically about Case ownership not changing after a Medical Inquiry is submitted. Salesforce Help for Medical Inquiries shows that the inquiry workflow uses Case status values such as Draft, Signed, Submitted, and Assigned, and Life Sciences Cloud also provides Trigger Handler Administration for configuring Life Sciences trigger handlers, including trigger handlers related to Case objects.
In the scenario, the status update is working correctly: the signed inquiry becomes Submitted. That means the submission process itself is functioning. The failure is isolated to ownership routing: the Case remains owned by the field sales rep instead of being routed to the Medical Science Liaison team or queue. Based on the available options, CaseChangeOwnershipHandler is the handler that directly corresponds to changing ownership on the Case record.
Option B, MSLInquirySubmissionHandler, sounds related to Medical Inquiry submission, but the submission status already updates correctly, so that is unlikely to be the inactive piece. Option C, CaseMSLQueueHandler, sounds like queue routing, but the Salesforce-style handler name that most directly describes the failed behavior is CaseChangeOwnershipHandler. Since the issue is ownership transfer after submission, the inactive trigger handler is CaseChangeOwnershipHandler.
=========
NEW QUESTION # 24
Choose 1 option.
Cumulus Pharma has configured and activated a new agent using the Life Sciences Field Sales template. However, when a field sales rep attempts to use the agent to generate a summary for a targeted Healthcare Provider (HCP), they are unable to access the feature. Reps must have the privileges required to interact with these capabilities.
Which permission set should the Agentforce Life Sciences Consultant assign to grant access to these Agentforce features?
Answer: A
Explanation:
Option C is correct because Salesforce Help identifies "Access Life Sciences Customer Engagement Agentforce" as the permission required for Life Sciences Customer Engagement Agentforce capabilities. In the Salesforce Help reference for the Life Sciences "Generate Healthcare Provider Summary" action, Salesforce lists the required access as Access Life Sciences Customer Engagement Agentforce. It also notes that, to run flows associated with agent actions, users need the Run Flows app permission or access to the individual flows.
This directly matches the scenario. The Life Sciences Field Sales agent template has already been configured and activated, but the field sales rep cannot use the agent-generated HCP summary capability. That means the issue is not the existence of the agent or the template; it is the user's permission to access the Life Sciences Customer Engagement Agentforce features. Salesforce's Account Summarization permissions documentation also references Access Life Sciences Customer Engagement Agentforce as part of the permission setup for account summarization, alongside standard Life Sciences user permission sets.
Option A, Life Sciences Commercial User, is not specific enough to grant access to these Agentforce capabilities. Option B, Agentforce Service Agent User, relates to Agentforce service use cases and is not the Life Sciences Customer Engagement permission named in the documentation. Therefore, the consultant should assign Access Life Sciences Customer Engagement Agentforce.
NEW QUESTION # 25
Choose 1 option.
A Cumulus Pharma field sales rep uses the Medical Insights feature in Agentforce Life Sciences for Customer Engagement to record insights from engagements with Healthcare Providers (HCPs). The company also uses an external system to generate intelligence from medical insights collected through various sources.
Which configuration sends the medical insights captured by the rep to the external system without delay?
Answer: C
Explanation:
The correct answer is B because the requirement is to send Medical Insights to an external system without delay, which points to an event-driven integration pattern. Salesforce's Life Sciences Cloud Developer Guide defines MedicalInsight as important information observed or heard through outlets such as meetings, calls, or research and used to inform strategy or follow-up. For near-real-time downstream processing, the appropriate Life Sciences configuration is to publish the standard Medical Insight platform event by activating the handler designed for that purpose.
Activating PublishMedicalInsightEventHandler allows newly captured Medical Insight data to be published as a MedicalInsightEvent platform event. Platform events are the correct Salesforce pattern when an external system needs to subscribe and react quickly as records are created or changed. This avoids waiting for scheduled jobs, exports, or manual data transfers, and it supports timely intelligence generation from field-captured insights.
Option A is incorrect because creating a custom platform event is unnecessary when the Life Sciences feature provides a standard MedicalInsightEvent mechanism. Custom events add avoidable implementation and maintenance complexity. Option C is also incorrect because MedicalInsightIntegrationHandler is not the specific handler described for publishing the MedicalInsightEvent platform event. The key words in the question are "without any delays," which make an event-based publishing configuration the best fit. Therefore, the consultant should activate PublishMedicalInsightEventHandler.
=========
NEW QUESTION # 26
......
The pass rate is 98% for ALS-Con-201 exam bootcamp, if you choose us, we can ensure you that you can pass the exam just one time. In addition, we offer you free demo to have a try before buying, so that you can know what the complete version is like. In order to strengthen your confidence for ALS-Con-201 training materials, we are pass guarantee and money back guarantee, and we will refund your money if you fail to pass the exam. We have a professional service team and they have the professional knowledge for ALS-Con-201 Exam Bootcamp, if you have any questions, you can contact with them.
Cert ALS-Con-201 Guide: https://www.dumpsmaterials.com/ALS-Con-201-real-torrent.html
P.S. Free 2026 Salesforce ALS-Con-201 dumps are available on Google Drive shared by DumpsMaterials: https://drive.google.com/open?id=1rOC5EiWrA7wd-7GoDGsALMhgVdh2Eq6R